In the KEYNOTE-001 trial, increased density of CD8+ T cells at the invasive margin or within the tumor parenchyma in the pretreatment samples was significantly associated with response to single-agent pembrolizumab in patients with melanoma [21]. Here, CD8A is linked to melanoma.